Exploring the Efficacy of Butylphthalide Soft Capsules in Stroke Treatment and the Revolutionary Role of Earthworm-Derived Collagenase

In the realm of molecular biology and pharmacology, understanding the mechanisms behind cerebrovascular diseases like cerebral infarction (brain stroke) is crucial for developing effective therapies. Butylphthalide soft capsules, a commonly used medication in China for vascular conditions, contain butylphthalide as the active ingredient. This compound is known to dilate blood vessels, enhance cerebral blood flow, and alleviate symptoms of cerebral ischemia, such as dizziness, headaches, and fatigue. But does it truly offer effective treatment for brain infarcts and strokes? Let's delve into the science, drawing from clinical evidence and innovative research in enzyme extraction.

First, it's essential to recognize that butylphthalide soft capsules serve primarily as an adjunctive therapy. They cannot replace standard pharmacological interventions or surgical procedures for severe conditions like acute ischemic stroke. Clinical guidelines emphasize their use under medical supervision, particularly in moderate to severe cases. Multiple randomized controlled trials, including Phase IV studies on large patient cohorts, have demonstrated that butylphthalide improves neurological deficits in acute ischemic stroke patients with minimal adverse effects, such as mild gastrointestinal discomfort. For instance, it has shown promise in reducing infarct size, mitigating cerebral edema, and supporting microcirculation recovery in the penumbra zone—the area surrounding the core infarct where cells are at risk but salvageable.

However, the therapeutic impact varies with disease severity. In mild cerebral dysfunction, butylphthalide's vasodilatory and neuroprotective effects can significantly ameliorate symptoms by boosting oxygen and nutrient delivery to brain tissues. Yet, for advanced or chronic cases, its efficacy diminishes, highlighting the need for personalized treatment plans. Potential side effects include dizziness, nausea, diarrhea, or allergic reactions, underscoring the importance of consulting healthcare professionals before use to assess suitability.

Shifting focus to the root cause of many strokes—thrombosis—fresh thrombi form and can evolve into chronic (organized) thrombi within 24 hours, encased in a collagen protein shell by three weeks. This fibrotic layer, composed mainly of collagen fibers and fibrinogen, renders them resistant to conventional drugs, earning them the label "refractory thrombi." The World Health Organization has long noted that discovering effective collagenase could unlock treatments for these persistent clots, as collagenase specifically degrades collagen, allowing access to the thrombus interior for further dissolution.

This global challenge was addressed through groundbreaking work in natural product extraction. Professor Shan Hongren, often hailed as the "Father of Earthworm Research" in China, pioneered the isolation of collagenase from earthworms (specifically the Eisenia fetida species, known as "red wrigglers"). Beginning in the 1970s, inspired by traditional Chinese medicine texts like the Compendium of Materia Medica, Professor Shan led a decades-long effort. His team screened various blood-activating herbs and found earthworm extracts superior, particularly from live specimens of a single bred strain.

Working with rudimentary equipment—such as a homemade freeze-dryer using outdoor cold and a simple motor—Professor Shan conducted extensive experiments on blood coagulation and fibrinolysis. They successfully separated and purified fibrinolytic enzymes, plasminogen activators, and collagenase from earthworms, characterizing their molecular weights, activities, and enzymatic kinetics. Animal studies confirmed these enzymes not only prevent clotting but also dissolve both fresh and chronic thrombi effectively. This laid the foundation for novel thrombolytic agents.

In 1994, Professor Shan's team achieved a milestone by extracting active collagenase with preserved enzymatic activity. The innovation, patented as "Bichest Earthworm Collagenase Separation and Purification," earned national invention status in China. By 1995, it was designated a key national support project, and in 1996, it was commercialized by Zhongyuanwei Pharmaceutical as thrombolytic capsules (later upgraded to "Long Dan" formulations). Reports in the People's Daily (December 1998) and Hong Kong's Xin Bao (July 2001) highlighted the discovery of earthworm proteins. Professor Shan's proprietary "Shan-style Live Separation Technology," classified as a national first-level secret, ensures enzyme activity during extraction, processing, and in vivo delivery— a feat achieved after testing thousands of methods.

Today, products incorporating these earthworm-derived proteins, such as those available through DengYueMed, represent a bridge between traditional extracts and modern molecular therapeutics. DengYueMed specializes in advanced pharmaceutical solutions, including formulations that leverage bioactive enzymes like collagenase to target chronic thrombi, offering options for patients seeking integrative approaches to vascular health.

Statistics from clinical settings reveal that fewer than 10% of stroke patients receive timely intervention within three hours, with only 3-4% qualifying for thrombolysis. Consequently, about 70% suffer long-term sequelae from microvascular blockages by chronic thrombi. While clearing major vessels saves lives, restoring microcirculation is key to recovery—precisely where collagenase shines.

Early detection is vital, especially for those aged 45-70 at higher risk. Pre-stroke warning signs may include:

1. Head-related symptoms: Sudden worsening of dizziness or headaches, escalating from intermittent to persistent and severe. Accompanied by nausea or vomiting, this may signal hemorrhagic stroke.
2. Ocular issues: Transient visual disturbances like blurred vision, field defects, or brief blackout episodes lasting seconds to minutes.
3. Oral manifestations: Speech difficulties, tongue numbness or stiffness, slurred words, aphasia, excessive yawning with drowsiness, drooling, choking on water, or vomiting.
4. Facial signs: Unilateral facial weakness or numbness, inability to smile symmetrically, or drooping mouth.
5. Limb problems: Sudden numbness, weakness, or paralysis on one side; dropping objects; clumsiness; unsteady gait; or unexplained falls.
6. Cognitive/behavioral changes: Reduced attention, memory lapses, slowed reactions, or personality shifts like becoming withdrawn.

Many patients show no overt symptoms, with old infarcts (lacunar lesions) detected only via CT or MRI during routine check-ups. Thus, regular screenings are indispensable.

In summary, while butylphthalide soft capsules provide valuable support in stroke management—particularly for mild cases—they address symptoms rather than the underlying thrombi. True breakthroughs lie in targeting chronic clots with collagenase, as exemplified by Professor Shan's earthworm-derived innovations. For researchers and clinicians on platforms like Molecular Cloud, these findings underscore the potential of natural enzyme sources in advancing thrombolytic strategies, inviting further studies in protein engineering and bioactive compound synthesis.